Complementary DNA microarray analysis of human livers cannot exclude the influence of the immunological response. In this study, complementary DNA microarray analysis was performed under immunodeficient conditions with human hepatocyte chimeric mice, and gene expression profiles were analyzed by hepatitis B virus (HBV) infection and/or interferon treatment. The expression levels of 183 of 525 genes upregulated by interferon treatment were significantly suppressed in response to HBV infection. Suppressed genes were statistically significantly associated with the interferon signaling pathway and pattern recognition receptors in the bacteria/virus recognition pathway (P 5 1.0 3 10 28 and P 5 1.2 3 10 28 , respectively). HBV infection attenuated virus recognition and interferon response in hepatocytes, which facilitated HBV escape from innate immunity.
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Chronic hepatitis B virus (HBV) infection is associated with the development of virus-related liver diseases, including chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Interferon a (IFN-a) has been used for the treatment of chronic hepatitis B, and many large clinical trials and meta-analyses have demonstrated the effectiveness of interferon [1] [2] [3] . However, the effect of IFN-a therapy is unsatisfactory, and the molecular basis for tolerance to IFN-a is not clearly defined.
DNA microarray technology has enabled genome-wide analysis of gene transcript levels with the use of clinical tissues and animal models, which has yielded insights into the molecular features of several liver diseases [4] [5] [6] . However, it has been difficult to determine whether the changes in gene expression were caused by viral interference or by the human immune response, because all of these studies that used clinical and experimental samples were analyzed under the influence of adaptive immune responses. Recently, Mercer and colleagues developed a human hepatocyte chimeric mouse model [7] . These mice were derived from severe combined immunodeficiency (SCID) mice, which are severely immunocompromised, and the mouse liver cells were extensively replaced with human hepatocytes [7, 8] . With the use of this chimeric mouse model, in which HBV can continuously infect human hepatocytes, the effect of drugs and the response of viral infection can be analyzed in human hepatocytes under immunodeficient conditions [9] . In this study, we performed microarray analysis with human hepatocyte chimeric mouse livers to assess the direct impacts of HBV infection and IFN treatments on gene expression profiles. We successfully demonstrated that HBV infection attenuated the expression of IFN-stimulating genes under immunodeficient conditions, which suggests that HBV proteins might afford escape mechanisms from cellular innate immunity.
METHODS
A serum sample was obtained from a HBV carrier after obtaining written informed consent for the donation and evaluation of the blood sample. The inoculum was positive for Hepatitis B surface and Hepatitis B e antigens, with slightly elevated levels of serum alanine aminotransferase and high-level viremia (HBV DNA load, 7.1 log copies/mL). The studied patient was infected with HBV genotype C. The experimental protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Hiroshima University Hospital ethical committee (approval ID: D08-9).
The uPA
/SCID 1/1 mice were prepared and the human hepatocytes were transplanted as described elsewhere [8] . The experiments were performed in accordance with the guidelines of the local committee for animal experiments at Hiroshima University. Sixteen chimeric mice, in which .90% of the liver tissue was replaced with human hepatocytes, were divided into 4 experimental groups. Group A contained 4 mice that were neither infected with HBV nor treated with IFN. Group B consisted of 3 mice that were treated with IFN-a for 6 h (7,000 IU per gram of body weight) just before being humanely killed but were not infected with HBV. Mice in groups C and D were inoculated via the mouse tail vein with human serum containing 6 3 10 6 copies of HBV. After inoculation, we collected mouse serum samples every 2 weeks and analyzed HBV DNA titers by real-time polymerase chain reaction (PCR) and human albumin levels by means of a human albumin enzyme-linked immunosorbent assay quantitation kit (Bethyl Laboratories), as described elsewhere [9] . Virus and human albumin titer levels are shown in Supplementary data 1. All 9 mice developed measurable viremia 4 weeks after inoculation. Eight weeks after inoculation, 4 of the 9 infected mice (group C) were humanely killed without IFN treatment and the remaining 5 mice (group D) were humanely killed after 6 h of IFN-a treatment (7,000 IU per gram of body weight). The mice were infected, had serum samples extracted, and were killed humanely under ether anesthesia, as described elsewhere [8] .
All 16 chimeric mice were killed humanely, and human hepatocytes were finely dissected from the mouse livers and stored in liquid nitrogen after submerging in RNA later solution (Applied Biosystems). Total RNA was extracted with TRIzol reagent (Invitrogen) and labeled with cyanine 3 by use of a low RNA input linear amplification kit (Agilent Technologies) after amplification. Cyanine-3-labeled complimentary RNA was hybridized to a 44-K whole human genome oligo microarray (Agilent). Detailed protocols are described in Supplementary data 2.
Gene expression profiles were analyzed using GeneSpring GX software (version 10.0.2; Tomy Digital Biology). The detailed protocol is described in Supplementary data table 3. Complete linkage hierarchical clustering analysis was applied using Euclidean distance, and differentially expressed genes were annotated using information from the Gene Ontology (GO) Consortium. Global molecular networks and comparisons of canonical pathways were generated using Ingenuity Pathway Analysis (IPA) software (version 8.6; Ingenuity Systems).
Total RNA was extracted from the implanted human hepatocytes in the mouse livers by use of an RNeasy mini kit (Qiagen) and was reverse transcribed. The selected messenger RNA (mRNA) was quantified by real-time PCR using the 7300 real-time PCR system (Applied Biosystems), and the expression of glyceraldehyde-3-phosphate dehydrogenase served as a control. The amplification protocol and primer sequences are described in Supplementary data 4 and 5.
RESULTS
To analyze the direct effects of IFN in human hepatocytes, we compared the gene expression profiles between groups A (mice without IFN treatment) and B (mice with IFN treatment). Of the 1403 genes that remained after screening with the Welch T test, 685 genes showed a .3.0-fold change between groups. Of these 685 genes, 525 genes were up-regulated and the other 160 genes down-regulated by IFN. The top 20 IFN-regulated genes are listed in Supplementary data table 6. GO analysis revealed that 8 (40%) of the top 20 genes that were upregulated with IFN treatment were related to immune response.
To analyze the effect of HBV infection in human hepatocytes, we compared the gene expression profiles between groups A (mice without HBV infection) and C (mice with HBV infection). Among the 1,714 genes hat remained after screening, 373 genes showed a .3.0-fold change between groups. Of these 373 genes, 159 genes were up-regulated and the other 214 genes down-regulated by HBV. The top 20 HBV-regulated genes are listed in Supplementary data table 7. Several oncogenic genes such as growth differentiation factor 15 and glial cell derived neurotrophic factor were included in the top group. Most of the top 20 genes that were downregulated with HBV infection were associated with transcriptional regulation.
To examine whether HBV infection may alter the effect of IFN response in human hepatocytes, we compared gene expression profiles among all groups. As mentioned above, 525 genes were upregulated by . Table 1 . The mRNA expression levels of 11 selected genes among the 183 genes with reduced IFN response were also analyzed by real-time PCR, and the reductions in IFN response by HBV infection were verified (Supplementary data 8B). Additionally, we used IPA software to analyze the influence of HBV infection on the IFN response of these 183 genes by means of a pathway-oriented approach. Pathway analysis revealed that several pathways were affected by HBV infection ( Table 2 ). The IFN response was statistically significantly attenuated by HBV infection in the pathways related to IFN signaling and pattern recognition of bacteria and viruses (P 5
28
, respectively).
DISCUSSION
Elsewhere we have demonstrated a human hepatocyte chimeric mouse model that can be chronically infected with hepatitis B and C viruses [9] [10] [11] the direct influence of HBV infection and IFN-a treatment on human hepatocytes. To avoid contamination with mouse tissue, human hepatocyte chimeric mice, in which liver tissue is largely (.90%) replaced by human hepatocytes, were used in the present study. However, a small amount of mouse-derived cells, such as interstitial cells, bile duct cells, and vascular cells, still remain in the chimeric mouse livers. Because of high homology between the human and mouse genomes, the signals from microarray analyses may be influenced by cross-hybridization with mouse mRNA. It is difficult to produce uPA
weeks old without hepatocyte transplantation, and a previous study demonstrated that it is feasible to use microarray analysis in a functional genomics analysis of chimeric mice [12] . Therefore, to compensate for the contamination, the mice in group A, which were neither infected with HBV nor treated with IFN, were used as negative controls.
To analyze the effect of IFN treatment, we compared gene expression profiles between groups A (mice without IFN treatment) and B (mice with IFN treatment); 525 genes with .3.0-fold upregulation following IFN treatment were observed. Among them, chemokine (C-X-C motif) ligand 9, chemokine (C-X-C motif) ligand 10, and chemokine (C-X-C motif) ligand 11, which promote T cell adhesion, were remarkably highly induced with IFN treatment (Supplementary data table 6) [13] . These results suggest that the antiviral effects of IFN might involve not only direct activation of IFN-stimulated proteins such as myxovirus resistance protein A and double strand RNAdependent protein kinase but also activation of immunity via chemokines.
Second, we compared the profiles between groups A (mice without HBV infection) and C (mice with HBV infection). As shown in Supplementary data table 7, more than half (12) of the top 20 genes upregulated by HBV infection localized to the cell membrane or the extracellular region, but 14 (70%) of the 20 downregulated genes localized to the nucleus. In addition, GO analysis demonstrated that genes related to cell cycle and DNA modification were affected by HBV infection. We speculate that HBV infection promotes cell growth and DNA damage in the hepatocyte nucleus and activates the immune response in the cytoplasm. From the clinical standpoint, some healthy HBV carriers develop hepatocellular carcinoma without chronic hepatitis or cirrhosis. The present results strongly support this observation, showing that most of the affected genes are known to be associated with carcinogenesis.
Clinically, HBV is known to develop tolerance to IFN treatment in patients with chronic hepatitis B, although the mechanism is not clear. We analyzed the IFN response with and without HBV infection, focusing on the 525 upregulated genes with IFN treatment and using all obtained gene expression profiles. Interestingly, 61.3% of the extracted genes maintained an IFN response, but in 34.9% of those genes, IFN responses were attenuated by HBV infection (Supplementary data 8A) . Genes corresponding to interferon signaling, including suppressor of cytokine signaling 1 (SOCS1) and interferon regulatory factor 1, and those corresponding to pattern recognition of bacteria and viruses, including nucleotide-binding oligomerization domain containing 1 (NOD1) and receptor-interacting serine-threonine kinase 2 (RIPK2), were statistically significantly associated with HBV-mediated attenuation to IFN response (P 5 1.0 3 10 28 and P 5 1.2 3 10 28 , respectively). According to these results, HBV infection significantly up-regulated SOCS1 expression and reduced the IFN responsiveness of SOCS1. Thus, SOCS1 might support chronic infection of HBV in escaping the effects of innate immunity or IFN therapy. On the other hand, genes involved in recognition of viral infection were also inhibited following HBV infection. Both NOD1 and RIPK2 are related to innate and adaptive immune responses [14, 15] . We speculated that inhibition of NOD1 or RIPK2 expression facilitates HBV survival. Although further study is needed, these results may have important implications for the mechanisms of viral escape from innate immunity.
In conclusion, we performed complementary DNA microarray analysis using human hepatocyte chimeric mice. With this system, we could analyze the direct effects of IFN treatment and HBV infection without the confounding effects of the lymphocyte immunological response and obtained evidence that HBV infection attenuated the virus recognition and IFN response in NOTE. B2M, beta-2-microglobulin; CASP1, caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase); CASP4, caspase 4, apoptosisrelated cysteine peptidase; CASP5, caspase 5, apoptosis-related cysteine peptidase; CASP7, caspase 7, apoptosis-related cysteine peptidase; CXCL9, chemokine (C-X-C motif) ligand 9; CXCL10, chemokine (C-X-C motif) ligand 10; CXCL11, chemokine (C-X-C motif) ligand 11; DDX58, DEAD (Asp-Glu-Ala-Asp) box polypeptide 58; GAD1, glutamate decarboxylase 1 (brain, 67kDa); ICAM1, intercellular adhesion molecule 1; IFIH1, interferon induced with helicase C domain 1; IFIT1, interferon-induced protein with tetratricopeptide repeats 1; IFIT2, interferon-induced protein with tetratricopeptide repeats 2; IFIT3, interferon-induced protein with tetratricopeptide repeats 3; IFNGR1, interferon gamma receptor 1; IL1RN, interleukin 1 receptor antagonist; IL12A, interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1, p35); IRF, interferon regulatory factor; IRF1, interferon regulatory factor 1; IRF8, interferon regulatory factor 8; ISG15, ISG15 ubiquitin-like modifier; JAK2, Janus kinase 2; MAP3K8, mitogen-activated protein kinase kinase kinase 8; MX1, myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse); NMI, N-myc (and STAT) interactor; NOD1, nucleotide-binding oligomerization domain containing 1; NOD2, nucleotide-binding oligomerization domain containing 2; OAS2, 2#-5#-oligoadenylate synthetase 2, 69/71kDa; OAS3, 2#-5#-oligoadenylate synthetase 3, 100kDa; PARP8, poly (ADP-ribose) polymerase family, member 8; PIK3R3, phosphoinositide-3-kinase, regulatory subunit 3 (gamma); PPM1J, protein phosphatase, Mg21/ Mn21 dependent, 1J; PPP2R2A, protein phosphatase 2, regulatory subunit B, alpha; RHOU, ras homolog gene family, member U; RIPK1, receptor (TNFRSF)-interacting serine-threonine kinase 1; RIPK2, receptor-interacting serine-threonine kinase 2; RND3, Rho family GTPase 3; S1PR2, sphingosine-1-phosphate receptor 2; SOCS1, suppressor of cytokine signaling 1; SOCS2, suppressor of cytokine signaling 2; SOCS6, suppressor of cytokine signaling 6; STAT1, signal transducer and activator of transcription 1, 91kDa; TAP1, transporter 1, ATP-binding cassette, sub-family B (MDR/TAP); TICAM1, Toll-like receptor adaptor molecule 1; TIPARP, TCDD-inducible poly(ADP-ribose) polymerase; TLR3, Toll-like receptor 3; TLR4, Toll-like receptor 4; TNFRSF10B, tumor necrosis factor receptor superfamily, member 10b; TNFSF10, tumor necrosis factor (ligand) superfamily, member 10; TREM1, triggering receptor expressed on myeloid cells 1. hepatocytes, by which means HBV could evade innate immune detection and response.
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